Characteristics and Developments in Mesenchymal Stem Cell Therapy for COVID-19: An Update
Open Access
- 2 June 2021
- journal article
- review article
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-16
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) has so far resulted in over a hundred million people being infected. COVID-19 poses a threat to human health around the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been confirmed as the pathogenic virus of COVID-19. SARS-CoV-2 belongs to the β-coronavirus family of viruses and is mainly transmitted through the respiratory tract. It has been proven that SARS-CoV-2 mainly targets angiotensin-converting enzyme II (ACE2) receptors on the surface of various cells in humans. The main clinical symptoms of COVID-19 include fever, cough, and severe acute respiratory distress syndrome (ARDS). Current evidence suggests that the damage caused by the virus may be closely related to the induction of cytokine storms in COVID-19. No specific drugs or measures have yet to be shown to cure COVID-19 completely. Cell-based approaches, primarily mesenchymal stem cells (MSCs), have been identified to have anti-inflammatory and immune functions in COVID-19. Clinical studies about using MSCs and its derivativesexosomes for COVID-19 treatmentare under investigation. Here, we review the current progress of the biological characteristics, clinical manifestations, and cell-based treatment development for COVID-19. Providing up-to-date information on COVID-19 and potential MSC therapies will help highlight routes to prevent and treat the disease.Keywords
Funding Information
- Tianjin University Independent Innovation Fund (2020XYF-0041, 2020XRG-0027, 20JCQNJC01260, BLB19J006, 81971878)
- Natural Science Foundation of Tianjin Municipality (2020XYF-0041, 2020XRG-0027, 20JCQNJC01260, BLB19J006, 81971878)
- Opening Project of Military Logistics (2020XYF-0041, 2020XRG-0027, 20JCQNJC01260, BLB19J006, 81971878)
- National Natural Science Foundation of China (2020XYF-0041, 2020XRG-0027, 20JCQNJC01260, BLB19J006, 81971878)
This publication has 185 references indexed in Scilit:
- Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophagesExperimental & Molecular Medicine, 2014
- Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomesJournal of Extracellular Vesicles, 2013
- Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and DeltacoronavirusJournal of Virology, 2012
- Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyThe Lancet Neurology, 2012
- Allogeneic Human Mesenchymal Stem Cells Restore Epithelial Protein Permeability in Cultured Human Alveolar Type II Cells by Secretion of Angiopoietin-1*Journal of Biological Chemistry, 2010
- Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like ProfilePLOS ONE, 2010
- Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophagesExperimental Hematology, 2009
- Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lungProceedings of the National Academy of Sciences, 2009
- Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?Thorax, 2006
- A New Virus Isolated from the Human Respiratory Tract.Experimental Biology and Medicine, 1966